SILVER SPRING, MD
4 risk indicators measuring financial stability and operational resilience
Sign in with your work email to view Tuckman-Chang indicators
Sign In — Free (10 views/day)INTERNATIONAL PARTNERSHIP FOR MICROBICIDES INC, founded in 2002, is a community nonprofit that reported $10.0M in total revenue in fiscal year 2022. Revenue fell 51% from the prior year — a significant decline worth monitoring. Expenses of $12.8M exceeded revenue, resulting in a 29% operating deficit.
TO DEVELOP HIV PREVENTION PRODUCTS AND OTHER SEXUAL AND REPRODUCTIVE HEALTH TECHNOLOGIES FOR WOMEN, AND TO MAKE THEM AVAILABLE AND ACCESSIBLE WHERE THEY ARE URGENTLY NEEDED.
THE PRODUCT DEVELOPMENT (PD) DIVISION LED NON-CLINICAL, FORMULATION, MANUFACTURING, CHEMISTRY MANUFACTURING AND CONTROLS (CMC), ANALYTICAL, AND MATERIAL PLANNING AND SUPPLY ACTIVITIES FOR IPM'S...
THE PRODUCT DEVELOPMENT (PD) DIVISION LED NON-CLINICAL, FORMULATION, MANUFACTURING, CHEMISTRY MANUFACTURING AND CONTROLS (CMC), ANALYTICAL, AND MATERIAL PLANNING AND SUPPLY ACTIVITIES FOR IPM'S PRODUCTS. THIS DIVISION REMAINED RESPONSIBLE FOR PRODUCT SUPPLY AND ASSOCIATED ACTIVITIES (INCLUDING PRODUCT MANUFACTURING, PACKAGING, LABELING, DISTRIBUTION, STABILITY) AS WELL AS THE POST-USE TESTING OF DAPIVIRINE RINGS TO SUPPORT ADHERENCE ASSESSMENTS DURING CLINICAL TRIALS. IN 2022, THE PD TEAM ALSO CONTINUED EFFORTS RELATED COMMERCIAL MANUFACTURING OF THE DVR. THIS INCLUDED COMPLETING CAPACITY PLANNING WITH CRITICAL VENDORS SUCH AS THE DVR PRODUCT MANUFACTURING PARTNER, DAPIVIRINE DRUG SUBSTANCE MANUFACTURING PARTNERS AND SILICONE MANUFACTURING PARTNER. ADDITIONALLY, PD SUPPORTED THE COMPLETION MANUFACTURING SCALE-UP (1X TO 5X) PROCESS VALIDATION. THE 5X PROCESS VALIDATION SUCCESSFULLY COMPLETED IN 2022 AND WILL BE USED AS THE DVR MANUFACTURING SCALE GOING FORWARD. FURTHER TO THIS, THE PD TEAM CONTINUED CMC, FORMULATION AND ANALYTICAL ACTIVITIES RELATED TO THE DEVELOPMENT THE THREE-MONTH DVR AND THE MPT RING. AS OF SEPTEMBER 30TH, 2022, THE PRODUCT DEVELOPMENT ACTIVITIES TRANSFERRED TO THE POPULATION COUNCIL AS PART OF IPM'S DISSOLUTION AND THE ASSOCIATED FUNDING AGREEMENT WITH THE POPULATION COUNCIL.
THE REGULATORY AFFAIRS TEAM OVERSAW THE MONTHLY DVR REGULATORY PROCESS, PROVIDING LEADERSHIP IN DOSSIER PREPARATION, FILINGS AND POST-APPROVAL MAINTENANCE IN EUROPE, THE UNITED STATES, SOUTH AFRICA...
THE REGULATORY AFFAIRS TEAM OVERSAW THE MONTHLY DVR REGULATORY PROCESS, PROVIDING LEADERSHIP IN DOSSIER PREPARATION, FILINGS AND POST-APPROVAL MAINTENANCE IN EUROPE, THE UNITED STATES, SOUTH AFRICA AND OTHER TARGET AFRICAN COUNTRIES, WHERE PREPARATIONS ARE ONGOING FOR DVR MARKET INTRODUCTION. IMPORTANTLY, IN 2022, THE REGULATORY AFFAIRS TEAM MANAGED ALL POST-AUTHORIZATION MEASURES RELATED TO THE EMA POSITIVE SCIENTIFIC OPINION OF THE MONTHLY DVR. THIS DIVISION ALSO SUPPORTS ALL REGULATORY EFFORTS FOR OTHER IPM PRODUCTS ON THE PRODUCT DEVELOPMENT PATHWAY; THIS SUPPORT INCLUDES SUBMISSION AND MAINTENANCE OF INVESTIGATIONAL NEW DRUG (IND) DOCUMENTATION AND CONDUCTING REGULATORY AGENCY INTERACTIONS RELATED TO NEW PROTOCOLS FOR UPCOMING CLINICAL TRIALS. IN PARTNERSHIP WITH THE REGULATORY AFFAIRS TEAM, THE QUALITY ASSURANCE (QA) TEAM ENSURES PRODUCT DEVELOPMENT AND CLINICAL STUDIES ARE CONDUCTED IN COMPLIANCE WITH ALL APPLICABLE DRUG AND SAFETY LAWS. AUDITS ARE CONDUCTED DURING THE CONDUCT OF CLINICAL TRIALS TO PROVIDE ASSURANCE OF PROTOCOL COMPLIANCE, AND COMPLIANCE WITH INTERNATIONAL CONFERENCE ON HARMONIZATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE (ICH) GUIDELINES, GOOD CLINICAL PRACTICES (GCP), AND ALL APPLICABLE REGULATIONS. VENDOR AUDITS ARE ALSO CONDUCTED WHERE IPM'S CLINICAL, PRECLINICAL, OR CMC WORK IS BEING CONDUCTED. AS OF SEPTEMBER 30TH, 2022, THE REGULATORY AFFAIRS ACTIVITIES TRANSFERRED TO THE POPULATION COUNCIL AS PART OF IPM'S DISSOLUTION AND THE ASSOCIATED FUNDING AGREEMENT WITH THE POPULATION COUNCIL.
PROGRAM SUPPORT & ACCESS: IN 2022, IPM CONTINUED TO BUILD AWARENESS GLOBALLY ABOUT MICROBICIDES AND CREATE A FAVORABLE ENVIRONMENT IN SUPPORT OF MICROBICIDE PRODUCT DEVELOPMENT AND INTRODUCTION. THIS...
PROGRAM SUPPORT & ACCESS: IN 2022, IPM CONTINUED TO BUILD AWARENESS GLOBALLY ABOUT MICROBICIDES AND CREATE A FAVORABLE ENVIRONMENT IN SUPPORT OF MICROBICIDE PRODUCT DEVELOPMENT AND INTRODUCTION. THIS IS ACHIEVED BY INFORMING, EDUCATING, AND BUILDING SUPPORT FOR IPM'S WORK THROUGH COMMUNICATION MATERIALS, ADVOCACY AND DIRECT STAKEHOLDER ENGAGEMENT. IN CONJUNCTION WITH THESE EFFORTS, IPM ALSO CONTINUED WORK TO ENSURE THAT THE DVR CAN QUICKLY REACH THE WOMEN IN DEVELOPING COUNTRIES, WHO FACE THE HIGHEST RISK OF HIV. THIS WORK INCLUDES PARTNERING WITH A GLOBAL NETWORK OF ORGANIZATIONS, INCLUDING GOVERNMENT, PHARMACEUTICAL, HEALTH SERVICES, CIVIL SOCIETY AND ACADEMIC SECTORS, TO STRATEGICALLY PLAN FOR AFFORDABLE ACCESS TO THE DAPIVIRINE RING. AS OF SEPTEMBER 30TH, 2022, THE PROGRAM SUPPORT & ACCESS ACTIVITIES TRANSFERRED TO THE POPULATION COUNCIL AS PART OF IPM'S DISSOLUTION AND THE ASSOCIATED FUNDING AGREEMENT WITH THE POPULATION COUNCIL.
Financial Health Score (300–850) · Liquidity · Solvency · Sustainability · Efficiency
Sign in to view Trantor Score and financial metrics
Liquidity (40%) • Solvency (30%) • Sustainability (20%) • Efficiency (10%)
Sign In — Free (10 views/day)| 2022 | 2021 | Change | |
|---|---|---|---|
| Revenue | $9,961,492 | $20,220,623 | -0.5% |
| Expenses | $12,803,344 | $19,901,457 | -0.4% |
| Net Income | $-2,841,852 | $319,166 | -9.9% |
Comprehensive financial analysis: Altman Z-Score, liquidity, solvency, sustainability, efficiency, and growth metrics
Financial Distress Indicator
Liquidity & Cash Position
Sign in to view all financial metrics
Altman Z-Score • Liquidity Ratios • Solvency Analysis • Growth Indicators • Efficiency Metrics
Sign In| Name | Title | Hours/Week | Role | Reportable Comp | Other Comp | Total |
|---|---|---|---|---|---|---|
| ZEDA ROSENBERG | FOUNDER & CEO - UNTIL 12/2022 | 32.00 |
Officer
Director
|
$810,001 | $51,138 | $861,139 |
| PAMELA BARNES | DIRECTOR | 1.00 |
Director
|
$0 | $0 | $0 |
| ALEX COUTINHO | DIRECTOR | 1.00 |
Director
|
$0 | $0 | $0 |
| ANJA GIPHART | DIRECTOR | 1.00 |
Director
|
$0 | $0 | $0 |
| FLORENCE HOUN | DIRECTOR | 1.00 |
Director
|
$0 | $0 | $0 |
| HILDE FRAFJORD JOHNSON | DIRECTOR | 1.00 |
Director
|
$0 | $0 | $0 |
| MAUREEN LUBA | DIRECTOR | 1.00 |
Director
|
$0 | $0 | $0 |
| MARK MITCHNICK | DIRECTOR | 1.00 |
Director
|
$0 | $0 | $0 |
| TLALENG MOFOKENG | DIRECTOR | 1.00 |
Director
|
$0 | $0 | $0 |
| LILLIAN MWOREKO | DIRECTOR | 1.00 |
Director
|
$0 | $0 | $0 |
| KATHLEEN FLYNN EVP CHIEF | FINANCIAL OFFICER - UNTIL 12/2022 | 40.00 |
Officer
|
$511,891 | $45,515 | $557,406 |
| PATRICIA MAYER-BRENNAN EVP | REGULATORY AFFAIRS - UNTIL 06/2022 | 40.00 |
Key Emp
|
$413,065 | $39,406 | $452,471 |
| BRID DEVLIN EVP PRODUCT | DEVELOPMENT - UNTIL 09/2022 | 40.00 |
Key Emp
|
$340,064 | $59,410 | $399,474 |
| LIZA FOLSTEIN VP | HUMAN RESOURCES - UNTIL 12/2022 | 40.00 |
Highest
|
$427,358 | $58,615 | $485,973 |
| HOLLY SELTZER | VP, COMMUNICATIONS - UNTIL 06/2022 | 40.00 |
Highest
|
$272,045 | $17,436 | $289,481 |
| JEREMY NUTTALL VP | PRECLINICAL SCI. - UNTIL 09/2022 | 40.00 |
Highest
|
$231,920 | $43,170 | $275,090 |
| PATRICK SPENCE SR DIR | CHEM. & ANAL. SCI. - TIL 06/2022 | 40.00 |
Highest
|
$220,246 | $34,180 | $254,426 |
| ANITA GARG VP STRAT PLAN | & PROG. MGMT. - UNTIL 09/2022 | 40.00 |
Highest
|
$205,336 | $40,693 | $246,029 |
| Year | Revenue | Expenses | Assets | Net Income |
|---|---|---|---|---|
| 2022 | $9,961,492 | $12,803,344 | No data | $-2,841,852 |
| 2021 | $20,220,623 | $19,901,457 | $16,214,079 | $319,166 |
| 2020 | $20,164,784 | $20,752,154 | $23,470,693 | $-587,370 |
| 2019 | $25,249,274 | $24,773,576 | $28,113,782 | $475,698 |
| 2018 | $25,206,212 | $26,337,178 | $24,838,200 | $-1,130,966 |
Compare INTERNATIONAL PARTNERSHIP FOR MICROBICIDES INC with other nonprofits in Maryland and across the country.